SCHEMBL5207817

SCHEMBL5207817

CCOc1cc(-c2ccc(N(C)CCN(C)c3ccc(-c4cc(OCC)c(OCC)c(OCC)c4)nc3)cn2)cc(OCC)c1OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 4/20 0.39
HSD17B10 Q99714 4/20 0.39
GAA P10253 3/20 0.39
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 4/20 0.37
HPGD P15428 4/20 0.37
ALDH1A1 P00352 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
THRB P10828 1/20 0.37
NPC1 O15118 1/20 0.36
MAPK1 P28482 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
POLB P06746 2/20 0.35
MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5205364 0.92 MEN1 (0.41) MEN1KMT2AHSD17B10SMN1; SMN2KDM4E
SCHEMBL5208974 0.92 TSHR (0.39) MEN1KMT2ATSHRHSD17B10GAA
SCHEMBL5208568 0.84 CYP1A1 (0.37) MEN1KMT2ATSHRGAAKDM4E
SCHEMBL5207852 0.82 FYN (0.43)
SCHEMBL5207045 0.82 HRH3 (0.42) GAASMN1; SMN2ALDH1A1
SCHEMBL5203389 0.79 HRH3 (0.38) SMN1; SMN2ALDH1A1MAPK1
SCHEMBL5207725 0.79 ALDH1A1 (0.39) TSHRSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL5210909 0.79 KDM1A (0.37) MAPT
SCHEMBL5204558 0.78 FYN (0.40)
SCHEMBL6409202 0.78 SLC2A1 (0.34) TSHRGAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1403251-B1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE KOWA CO (JP) 2007-07-18 EP disclosed
US-6890940-B2 Bis(2-aryl-5-pyridyl) derivatives KOWA CO., LTD. (JP) 2005-05-10 US disclosed
EP-1403251-A1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE Kowa Co., Ltd. (JP) 2004-03-31 EP disclosed
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy IGLV6-57, IL5, IGSF11 MEN1 3218/4885KMT2A 2840/4885TSHR 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.